Race Oncology Ltd (ASX:RAC) Share Price

Company Profile

Business description
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.
Contact
1 Macquarie Place
Level 36, Gateway
SydneyNSW2000
AUS
T: +61 280513043
https://www.raceoncology.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees

Recommended

We were wrong when we thought last quarter would be hard to top.

Dan Romanoff, CPA | 31 July 2025

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 30 July 2025

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Shaun Ler | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,917.10	81.90	-0.91%
CAC 40	7,546.16	225.81	-2.91%
DAX 40	23,425.97	639.50	-2.66%
Dow JONES (US)	43,588.58	542.40	-1.23%
FTSE 100	9,068.58	64.23	-0.70%
HKSE	24,507.81	265.52	-1.07%
NASDAQ	20,650.13	472.31	-2.24%
Nikkei 225	40,799.60	270.22	-0.66%
NZX 50 Index	12,729.40	94.34	-0.74%
S&P 500	6,238.01	101.38	-1.60%
S&P/ASX 200	8,662.00	80.80	-0.92%
SSE Composite Index	3,559.95	13.26	-0.37%